INTRODUCTION:

Vildagliptin is associate degree oral anti-diabetic drug, potent dipeptide proteolytic enzyme IV (DPP-IV) matter for the treatment of diabetes^1,2. it's with chemicals⁵-1- 2-(3- Hydroxyadamantan- l-ylamino) acetylj pyrrolidine- 2-carbonitrile.³ DPP-IV inhibitors represent a brand new category of oral anti -hyperglycaemic agents to treat patients with type-2 diabetes⁴. DPP-IV inhibitor improves abstinence and postprandial glycaemic management while not hypoglycaemia or weight gain. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-IV, permitting GLP- I and GIP to heighten the secretion of hormone within the beta cells and suppress endocrine unleash by the alpha cells of the islets of Langerhans within the pancreas^5,6’. Literature survey disclosed that few analytical ways square measure used for estimation of Vildagliptin however there's no analytical methodology for the determination of Vildagliptin from its pharmaceutical dose type. because of lack of revealed liquid natural process ways for VDG, therefore the aim of this work was to develop a reversed-phase liquid natural process (RP-LC) methodology that may be appropriate for the determination of VDG from its pharmaceutical dose type. The projected methodology iseasy, accurate, duplicatable and appropriate for routine determination of Vildagliptin from its pharmaceutical dose type.^7,8.

Fig. 1. Structure of vildagliptin.

Drug profile:

DRUG	Vildagliptin
IUPAC Name	(2S)-1-{ 2-[(3-hydroxyadamantan-1-yl)amino]acetyl)pyrrolidine -2-carbonitrile
Chemical Formula	C _l7H₂₅N₃O₂
Molecular Mass	303.3993 g/mole
Melting Point	153— l55°C
Physical State	Solid
Solubility	Soluble in Water and Methanol
pKa	14.71 and 9.03 Strongest acidic and basic respectively
t1/2	90 minutes
Therapeutic Use	Used to reduce hyperglycemia in type 2 diabetes mellitus.

Pharmacology:

Figure one displays the chemical structure of vildagliptin, Vildagliptin may be a selective, reversible, competitive matter of DPP4,⁹an accelerator and binding macromolecule gift in several tissues like the kidneys, liver, brush border membranes of the internal organ, duct, lymphocytes, and epithelial tissue cells.¹⁰ Vildagliptin binds to and forms a posh with DPP4, leading to its inhibition.⁹ DPP4 is concerned within the inactivation of the many neuropeptides, cytokines, chemokines, and epithelial duct hormones.¹⁰ 2 necessary endocrine concerned in aldohexose equilibrium and inactivated by DPP4 area unit aldohexose dependent insulinotropic poly- amide (GIP) and GLP-1.^11,12 GIP and GLP-1 area unit incretins, that area unit hormones discharged from the gut that stimulate hypoglycaemic agent secretion in response to food intake¹³. However, GIP doesn't stimulate hypoglycaemic agent unharness in patients with sort a pair of DM because it will in patients while not polygenic disease.^14,l5 GLP- l, the foremost potentinsulinotropic endocrine, enhances glucose-dependent secretion of hypoglycaemia agent from exocrine gland exocrine gland and inhibits endocrine secretion.¹⁶ Inhibition of DPP4, which ends in increased levels of active GLP-1, has been shown to be an efficient treatment for sort a pair of polygenic disease mellitusFigure one displays the chemical structure of vildagliptin, Vildagliptin may be a selective, reversib1e,competitive matter of DPP4, (9) an macromolecule and binding super molecule gift in many tissues just like the kidneys, liver, brush border membranes of the inner organ, channel, lymphocytes, and epithelial tissue cells.^l0 Vildagliptin binds to and forms a flowery with DPP4, resulting in its inhibition.⁹ DPP4 worries inside the inactivation of the numerous neuropeptides, cytokines, chemokines, and duct hormones.^l0 a pair of necessary endocrine involved in hexose physiological condition and inactivated by DPP4 ar hexose dependent insulinotropic poly- organic compound (GIP) and GLP-1.^I1,12 GIP and GLP-1 ar incretins, that ar endocrines discharged from the gutthat stimulate hormone secretion in response to food intake^l3. However, GIP does not stimulate endocrine unhitch in patients with type a combine of polygenic disease as a result of it'll in patients whereas not inherited disease.^14,15 GLP-1, the foremost potentinsulinotropic endocrine, enhances glucose-dependent secretion of endocrine from duct gland duct gland and inhibits hormone secretion.¹⁶ Inhibition of DPP4, that ends in inflated levels of active GLP-1, has been shown to be a decent treatment for type a combine of polygenic disease.

Pharmacokinetics:

The disposition of vildagliptin has been described in both a preclinical study with healthy volunteers^l7 and another study in patients with type 2 diabetes mellitus.¹⁸ Participants in both studies received vildagliptin 100 mg orally; vildagliptin was rapidly absorbed, with a peak plasma vildagliptin concentration observed at one to two hours after the dose was given.¹⁸ Vildagliptin displayed an oral bioavailability of 85% in healthy volunteers, and its pharmacokinetics were not affected by food.¹⁹ An absolute oral bioavailability exceeding 90% and an average clearance rate from plasma of 1.5 L/hr./kg with a volume of distribution of 0.7L/kg were observed following a l- pmol/kg oral dose administered to cynomolgus monkeys²⁰.

Analytical methods for estimation of vildagliptin:

Estimation of vildagliptin by HPLC:

High-performance liquid activity (or high liquid activity, HPLC) could be a specific type of chromatography usually employed in organic chemistry and analysis to separate, identify, and quantify the active compounds.²¹

Sr.no	Drug name	Description	Reference
1.	vildagliptin	1. Mobile phase: Methanol and Ammonium hydroxide (25%), 2. Orthophosphoric acid (85%) 2. Flow rate: l.0ml/min 3. Detection: 2l0nrn 4. Retention Time: 6. Amin 4. Limit of detection: 1.47pg/ml 6. Limit of quantification: 4.90pg/ml 5. Calibration curve: 200pg/ml(r2=0.9997) 6. Percentage recovery: -99.11-100.62% 7. Column (150mmxd.6mm, 5pm).	22
2	Vildagliptin	1. Mobile phase: 0.IM phosphate Buffer, acetonitrile (86:15% v/v) 2. Flow rate: l.0ml/min 3. Detection: 210nm 4. Retention Time: more than l0min 5. Calibration curve: 10-150pg/ml 6. Column (Agilent XBB c18, 150 x4.6mm, 5pm).	23
3	Vildagliptin	1. Mobile phase: 0.OM Potassium dyhydrogen, phosphate buffer Acetonitrile 80:20v/v 2. Detection: 263nm 3. Retention Time: 2.6min 4. Calibration curve: 50- l75pg/ml 5. Limit of detection: 0.0182pg/ml 6. Limit of quantification: 0.0553pg/ml 7. Column Kromasil—c l8 (4.5x250mm, Sp m).	24
4	Vildagliptin	1. Mobile phase: Acetonitrile Methanol (70:10:20v/v) 2. Flow rate: 1.0ml/min 3. Detection: 2l0nrn 4. Retention Time:-10min.	25
S	Vildagliptin	1. Mobile phase: dil. Orthophosphoric acid solution, Acetonitrile (72:28v/v) 2. Flow rate: l.0ml/min 3. Detection: 266nrn 4. Retention Time: 3.25min 5. Limit of detection: 0.06pg/ml 6. Limit of quantification: 6.21pg/ml 7 Percentage recovery: 99.73% 8 Column (Altirna c18 column, l50mmx4.6mm,5pm).	26

Estimation of vildagliptin by UV-Spectrophotometer:

Number of ultraviolet (UV) spectrophotometric ways used for these purpose. However, among all of these ways, actinic ray spectrophotometry is favourite tool. The elemental principle behind the actinic ray spectroscopy is absorption of visible and actinic ray radiation (200 — four hundred rim) is said to excitation of electrons, in every atoms and molecules, from lower to higher energy levels. Since the energy levels of matter unit of measurement quantity, entirely light-weight with the precise amount of energy can cause transitions from one level to a unique or aiming to be absorbed²⁷.

Sr. No	Drug name	system	description	Ref.
l	Vildagliptin	Instruments: A UV-Visible spectrophotometer (Shimadzu UV—1800 spectrophotometer, Shimadzu, Japan)	1. So1vent: water 2. Wavelength: 294nm.	28
2	vildagliptin	A Schimadzu 1800 version 1.12-Double Beam UV-Visible spectrophotometer.	1. Solvent: NaOH, 2. H₂O₂, HCl, Ethanol. Wavelength:2l6nm	29
3	vildagliptin	UV-visible 1601, Schimadzu, double, beam spectrophotometer	1. Solvent: water 2. Wavelength:244nm	30

Estimation of vildagliptin by HPTLC:

High Performance thin Layer chromatography (HPTLC) is a mature and automatic type of the thin-layer chromatography (TLC) with higher and advanced separation efficiency and detection limits. It’s additionally referred to as High Pressure thin Layer Chromatography/Planar chromatography or Flat- bed chromatography. It’s a strong analytical technique equally appropriate for qualitative and quantitative analytical tasks^{3 l,32}.

Sr. No

Drug Name

Description

Reference

Vildagliptin

1. Stationary phase: Merck TLC plates percolated with silica gel 60 F25d (l0cm x 10cm).

2. mobile phase: chloroform: n-butanol: Methanol (5:2:3)

3. Detection: 227 nm.

4. Chamber saturation time: 20 min.

Estimation of vildagliptin by UPLC:

Ultra Performance Liquid Chromatography (UPLC) can be considering as a new direction for liquid chromatography. UPLC improves three areas of Liquid chromatography namely speed, separation, and sensitivity of analysis by using particle size less than 2 pm and the system is formed in a special way to withstand high system back-pressures. Under the very high pressure Cup to 100 Mpa) the separation on UPLC is performed. But it has no negative effect on other components of chromatographic system or analytical column and also decrease of time and solvent utilisation compare to HPLC. (34)

Sr. no

Drug

name

method

Description

Ref.

vildagliptin

UPLC

1. Stationary phase: separation. BEH C-18 (50 x 2.1 mm.1 7 km) column.

2. Mobile phase: 0.5% Acetic acid in methanol 0.02M ammonium acetate (10:90, v/v) at a flow rate of 0.5 mL/min in isocratic elution.

Validation parameter:

Validation is a fundamental part of any good analytical practice. Method for a specific test is suitable for its intended use.to judge the quality, reliability, and consistency of analytical results the method validation is used validation is the process used to confirm that the analytical procedure employed.(36)

For method validation USP has published the specific guideline’s defines eight steps for validation:

1. Accuracy:

2. Precision

3. Specificity

4. Linearity

5. Range

6. Detection limit

7. Quantitation limit

8. Robusteness

9. Ruggedness

10. Sensitivity

l l. Repeatability

12.Reproducibility

CONCLUSION:

Vildagliptin is anti-diabetic drug .it is approved in 2007 by USFDA. The above study gives the analytical methods for analysis of vildagliptin in bulk and tablet dosage form. Literature survey reveals that various methods are reported for the development and validation of various drugs. a present review illustrates various analytical approaches exercised for the evaluation of vildagliptin numerous investigation had perform including HPLC, HPTLC, UV, UPLC in bulk, and pharmaceutical dosage form. These methods are reported for the development and validation of various drugs. Analysis of drug plays a significant role during formulation to identify the drug and its metabolites.

REFERENCE:

1. Thornberry NA and Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice and Research Clinical Endocrinology and Metabolism. 2009;23(4):479-486.

2. McIntosh CHS, Demuth HU, Pospisilik JA and Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. Regulatory Peptides. 2005;128(2):159-165.

3. WWW. Drug Bank. com.

4. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Journal of Medicinal Chemistry. 2004;47: 4135-4141.

5. Mentlein R. Dipeptidyl-peptidase IV (CD26)- role in the inactivation of regulatory peptides. Regulatory Peptides. l999;85( l):9-24.

6. Moneeb MS. Spectrophotometric and spectrofluorimetric methods for the determination of Saxagliptin and Vildagliptin in bulk and pharmaceutical preparations. Bulletin of Faculty of Pharmacy. Cairo University. 2013;5l (2):139-150.

7. Ramzia I. El—Bagary, Ehab F. Elkady, Bassam M. Ayoub. Liquid Chromatographic Methods for the Determination of Vildagliptin in the Presence of its Synthetic Intermediate and the Simultaneous Determination of Pioglitazone Hydrochloride and Metformin Hydrochloride, International Journal of Biomedical Science 7(3), 201- 208, (2011)

8. Amanda Thomas Barden, Bàrbara Salamon, Elfrides Eva Sherman Schapoval, and Martin Steppe; Stability- Indicating RP-LC Method for the Determination of Vildagliptin and Mass Spectrometry Detection for a Main Degradation Product, J Chromatogr Sci 50(5): 426-432, (2012).

9. Brandt I, Joossens J, Chen X et al. Inhibition of dipeptidyl-peptidase lV catalyzed peptide truncation by vildagliptin ((2S)- ( [(3-hydroxyadamanta-1-yl) amino]acetyl }-pyrrolidine-2-carbonitrile). Biochem Pharmacol. 2005; 70:134-43.

10. Mentlein R. Dipeptidyl-peptidase lV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999; 85:9-24.

11. Efendic S, Portwood N. Overview of incretin hormones. Horm Metab Res. 2004; 36:742-6.

12. Villhauer EB, Brinkmn JA, Naderi GB et al. 1 -[[(3-hydroxy- l-adamantyl)aminolacetyl]-2-cyano- (S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase lV inhibitor with antihyperglycemic proper- ties. J Med Chem. 2003; 46:2774-89.

13. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003; 3:365-72.

14. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide l [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91:301-7.

15. Elahi D, McAloon-Dyke M, Fukagawa NK et al. The insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994; 51:63-74.

16. Barlocco D. LAF-237. Curr Opin Invest Drugs. 2004; 5:1094-100.

17. Tran P, Yin H, Smith T et al. Disposition of [l4C]LAF237 in rats and humans. Drug Metab Rev. 2002; 34:147. Abstract.

18. He YL, Balch A, Campestrini J et a1. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes. Clin Pharmacol Ther. 2005; 77:P56. Abstract.

19. Pratley RE, Salsali A, Matfin G. Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes. Br I Diabetes Vase Dis. 2006; 6:150-6.

20. Villhauer EB, Brinkmn JA, , Naderi GB et al. 1-[[(S-hydroxy- l- adamantyl)amino]acetyl]-2-cyano- (S)- pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003; 46:2774-89.

21. Martin M., Guiochon, G. Effects of high pressures in liquid chromatography. J. Chromatogr. A, 2005; (1-2)7: 16-38.

22. Aparajita Malakar, Bishwajit Bokshi, Dilruba Nasrin. Development And Validation Of Rp-Hplc Method For Estimation of Vildagliptln From Tablet Dosage Form) ,International Journal of Pharmaceutical and Life Sciences. Volume l, Issue 1, Serial 2: August 2012.

23. Thangabalan Boovizhikannan, Vijayaraj Kumar Palanirajan, RP-HPLC determination vildagliptin in pure and tablet formulation journal homepage: www.elsevier.com/locate/jopr, Received 6 November 2012 Accepted 9 January 2013 Available online 4 February 2013.

24. Ramesh Jayaprakash, Senthil Kumar Natesan), stability indicating RP-HPLC method development and validation for the simultaneous determination of vildagliptin and metformin in pharmaceutical dosage form , International Journal of Pharmacy and Pharmaceutical Sciences. Vol 9, Issue 3, 2017.

25. Meetali M. Chaphekar, Purnima D. Hamrapurkar. Development and validation of RP-HPLC assay method for vildagliptin using QBD approach and its application to forced degradation studies. International Journal of Pharmaceutical Sciences and Drug Research ,2016; 8(S): 157-165 .

26. K. Hanumantrao, A. Laxmanrao and KB. Chandrasekhara, Development and validation HPLC method for the estimation of vildagliptin in pharmaceutical dosage form. International Journal of Pharmaceutical, Chemical and Biological Sciences.

27. Pavia D, Lampman G, Krix G. Introduction to Spectroscopy. Bloomington, IN: Indiana University; 2001. 28.

28. Sujan Banik, Palash Karmakar and Md. Anowar Hossain Miah, Development and Validation of a UV - Spectrophotometric Method for Determination of Vildagliptin and Linagliptin in Bulk and Pharmaceutical Dosage Forms, Bangladesh Pharmaceutical Journal 18(2): 163-168, 2015.

29. P. V. Prasad, K. Divya, M.V. Ramana, A. Krishnaveni, J. Vinay, M. Mahadeswar. Analytical method development and validation for the estimation of vildagliptin in bulk and its dosage form using UV spectrophotometer, Indo American Journal of Pharmaceutical Research, 2017.

30. Dr, Safila Naved, Hina Rehman, Fatima Qamar and Syeda Zainab. Method development and validation of vildagliptin using UV Spectrophotometer, International Journal Of Pharma Science and Research(IJPSR) October 2014 volume 5 P.G. no.714-717.

31. Sharma A., Shanker C., Tyagi L. K., Singh M., Rao V. Herbal Medicine for Market Potential in India: An Overview. Academic J. Plant Sci. 2008; 1 (2): 26-36.

32. Kadam P. V., Yadav K. N., Shivatare R. S., Pande A. S., Patel A. N., Patil M. J. Standardization of Gomutra Haritaki Vati: An Ayurvedic Formulation. Int. J. Pharm. Bio. Sci. 2012; 3 (3): 181—187.

33. K. R. Patil, T. A. Deshmukh and V. R. Patil. A stability indicating HPTLC method development and validation for analysis of vildagliptin as bulk drug and from its Pharmaceutical Dosage Form, Intonational Journal Of Pharmaceutical Science And Research,(IJPSR)2020,volume 1, issue 5,p.g. no.2310-2316.

34. B. M. Ghule P. Ghule A.V., Darandale A.S, Wagh I. GI, Ultra performance liquid chromatography: a new revolution in liquid chromatography, International Journal of Pharmaceutics and Drug Analysis, Vol: 2; Issue: l Page:25- 34.

35. Ramzia I. El Bagary, Hassan M. E. Azzazy, Ehab F. ElKady and Faten Farouk, Simultaneous determination of metformin, vildagliptin, and 3-amino-1-adamantanol in human plasma: Application to pharmacokinetic studies, Journal of Liquid Chromatography and Related Technologies. Date: 31 May 2016, At: 11:21.

36. Sunila T. Patil, Rajesh A. Ahirrao, Sunil P. Pawar, A short review on method validation, SPER Publications and Solutions Pvt. Ltd.

Received on 24.02.2021 Modified on 11.02.2021

Research Journal of Science and Technology. 2021; 13(2):157-162.

DOI: 10.52711/2349-2988.2021.00024